March 18, 2013
Last week I posted some of the latest legislative proposals out of the 113th Congress that would affect either some aspect of the pharma industry or FDA. That information is housed on a tab on the Eye on FDA site … Continue reading →
February 26, 2013
As I mentioned last week, I have put together a data base – a constant work in progress – of pharma activities in social media. One of the fields on which I can perform sort on is one where I … Continue reading →
May 22, 2012
It goes without saying that as Twitter develops as a platform, the uses of it increasingly vary. In fact, Twitter allows not only for a breadth of uses – from journalistic to scientific – but a depth as well (despite … Continue reading →
September 4, 2009
In today's environment there is a dichotomy for the pharmaceutical industry when it comes to good corporate social responsibility. Here it is. In the aggregate, the pharmaceutical and biotech industry actually provide a very very large contributions through philanthropy that … Continue reading →
February 24, 2009
What? What is a 483? A 483 is the vernacular for an FDA inspection of quality standards, manufacturing or the conduct of a clinical trial, and the discovery of deficiencies therein. In other words, theygo through your manufacturing facility, for … Continue reading →